Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Call it a major breakthrough for diagnostic imaging
Call it a major breakthrough for diagnostic imaging
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
Subscribe To Our Newsletter & Stay Updated